Home › Triple-Negative Breast Cancer › New York
Triple-Negative Breast Cancer clinical trials in New York
46 studies for Triple-Negative Breast Cancer are looking for participants at sites in New York.
Cities in New York
- New York City31 studies
- Queens15 studies
- Buffalo7 studies
- Greenburgh7 studies
- Staten Island5 studies
- New Rochelle5 studies
- The Bronx3 studies
- Syracuse3 studies
- Rochester3 studies
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New York Long Island LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05422794First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- NYU Longone Health (Long Island), Long Island City
- NYU Longone Health (Manhattan), Manhattan
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Mineola
- Avenzo Therapeutics Recruiting Site, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- NYU Langone Medical Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073), Mineola
- Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York
- Memorial Sloan Kettering Cancer Center ( Site 0067), New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374Intratumoral N17350 in Advanced Solid Tumors
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06246968First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Mount Sinai, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06657222A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05570253Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- NYP/Weill Cornell Medical Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT03606967Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Hematology Oncology Associates of Central New York, PC, East Syracuse
- Northwell Health, Lake Success
- Laura and Isaac Perlmutter Cancer Canter, New York
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- NYU Langone Health - Long Island, Mineola
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
- SUNY Upstate Medical University, Syracuse
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07743190A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 70 and older · All sexes · Updated Aug 17, 2026 · NCT07768436Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT05985655A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Memorial Sloan Kettering Cancer Center, New York
- Local Institution - 1037, Syracuse
- Clinical Research Alliance, Westbury
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06150664A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street., New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07318805Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT04348747A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Study of XB010 in Subjects With Solid Tumors
- Montefiore Medical Center - Montefiore Medical Park, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT06545331A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START New York Long Island, LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07503808BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT05768932A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04300556Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
- Mount Sinai Health System, New York
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated May 14, 2026 · NCT06637306I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Roswell Park Cancer Institute, Buffalo
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York
- Columbia University Medical Center, New York
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 24, 2026 · NCT06434064A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- NYU Langone perimutter Cancer Center, New York
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Apr 20, 2026 · NCT06134375Access to Genetic Testing in Underserved Patients With Cancer
- University of Rochester, Rochester
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Mar 18, 2026 · NCT06422455A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06908928Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Memorial Sloan Kettering Cancer Center @ Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT03808337A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Feb 17, 2026 · NCT04683679From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.